Get Help Now


Illinois Investigating Prescription Pain Medication

Drug companies can face serious penalties for promoting a drug for an off-label useThe Office of the Attorney General of Illinois, other state attorneys general, and the federal government have all notified Insys Therapeutics that they are investigating the drug company’s conduct with regard to a specific prescription pain medication known as Subsys Fentanyl.

What Is Subsys Fentanyl?

Subsys Fentanyl is an opiate painkiller that patients use as an oral spray. It is approved by the U.S. Food and Drug Administration (FDA) for use by adult patients with late stage cancer who are already taking opiate medication but who are experiencing breakthrough pain. This drug is among the strongest and potentially dangerous and addictive pain medications available.

Why Is the State of Illinois Concerned?

According to NBC News, Illinois and other states are concerned with how Insys Therapeutics is marketing Subsys Fentanyl. It is alleged that Insys Therapeutics pressured its sales representatives to convince doctors to write Subsys Fentanyl prescriptions for patients who did not have cancer, but instead suffered from other medical conditions such as migraines, neck pain, and other illnesses.

Doctors may legally write prescriptions for FDA approved drugs for purposes other than which the FDA has approved the medication; however, it is illegal for pharmaceutical companies to market medications for such off-label uses.

What Should You Do If You’ve Been Hurt Subsys Fentanyl?

Serious side effects, such as respiratory distress and drug abuse, have been reported with this medication. If you have been hurt or a loved one has died from Subsys Fentanyl, then it is important to find out more about your rights and your possible recovery. Please start a live chat with us now to get the information that you need and to schedule a free consultation with an experienced Illinois attorney.

Jason F. Abraham
Managing Partner, Hupy and Abraham
Be the first to comment!
Post a Comment